Pioneering engineered cell and gene therapies to deliver transformative outcomes for patients. A preclinical stage cell therapy company focused on addressing solid tumors. The company is based on a platform technology (called cytoDRiVETM) out of Tom Wandless’s lab at Stanford, which allows it to control protein degradation using FDA-approved small molecules, permitting precise control of the timing and level of protein expression.